For the roughly 1,500 Americans diagnosed each year with a slow-growing but relentless form of brain cancer called grade 2 glioma, the treatment options have historically been grim: surgery, radiation, chemotherapy — or watchful waiting. On August 15, 2024, that calculus changed.
The U.S. Food and Drug Administration approved vorasidenib — sold as Voranigo — for patients with astrocytoma or oligodendroglioma whose tumors carry a specific genetic mutation. It is the first systemic therapy ever approved for these patients. Systemic, meaning a pill taken by mouth that travels through the bloodstream to reach the tumor. No surgery. No radiation. No chemo drip.
The drug works by blocking two mutant proteins, IDH1 and IDH2, that are common in these cancers. Those mutations cause cells to churn out too much of a metabolite called 2-hydroxyglutarate, or 2-HG. That metabolite gums up the machinery of normal cell development, pushing healthy cells down the path to malignancy. Vorasidenib stops that overproduction. It forces malignant cells to differentiate — to mature and stop dividing.
This is targeted therapy, not carpet bombing.
The approval did not come out of nowhere. The FDA had granted vorasidenib breakthrough therapy designation and priority review, signaling early on that the data looked strong. Clinical trials showed the drug delayed tumor growth and postponed the need for more aggressive treatments. For patients facing a diagnosis that can steal years of life, that delay matters.
Still, the drug is not a cure. It is a management tool. And it comes with side effects. The most common adverse reactions reported in trials included fatigue — a vague word that in cancer care can mean everything from mild tiredness to bone-deep exhaustion. Other side effects were noted but not detailed in the FDA announcement.
The approval marks a shift in how doctors think about low-grade gliomas. For decades, the standard was to cut, burn, or poison the tumor. Now, for a subset of patients defined by a specific molecular fingerprint, there is a fourth option: inhibit the engine driving the cancer.
The IDH1 and IDH2 mutations are not found in all gliomas. They are most common in grade 2 astrocytomas and oligodendrogliomas. That narrows the eligible patient pool. But for those who carry the mutation, the drug offers something the older treatments could not: specificity. It targets the mutant protein while leaving the healthy version largely alone.
The science behind this is not new. Researchers have known for years that IDH mutations are a driving force in these cancers. The challenge was designing a molecule that could cross the blood-brain barrier and hit the target inside the tumor cells. Vorasidenib, an oral inhibitor, appears to do that.
The approval also sends a signal to the field. The FDA is willing to approve drugs for rare cancers based on strong Phase 3 data, even when the endpoint is not overall survival but progression-free survival — time before the tumor grows. That is a lower bar, but for a disease with few options, it is a meaningful one.
For patients and their families, the news is straightforward: there is now a pill that can buy time. Time before the next MRI shows growth. Time before the next surgery. Time before radiation.
The drug is not for everyone. It is for those with the right mutation. And it is not without risk. But on August 15, the treatment landscape for grade 2 glioma shifted. Not by inches. By a clear, measurable step forward.
